PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

59.24 1.75 −2.87%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
110×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(124.24%) (104.75%) 101.97% 20.64%
Piotroski F-Score
7 7 1 2
ROA
33.51% 29.66% (6.76%) (1.30%)
ROIC
90.05% 121.13% (6.74%) 15.16%
Return on Tangible Assets
62.72% 50.16% (13.50%) (2.02%)
Average Days of Receivables
41.66 38.30 97.05 86.49
Free Cash Flow per Share
5.69 8.83 (5.85) (3.62)
Free Cash Flow
446.32 702.41 (482.67) (300.25)
Capital Expenditures
(269.15) (8.79) (264.72) (269.74)
Other line items
Cash ROIC
11.40% 16.19% (11.16%) (6.03%)
Accounts Receivable Turnover
8.83 10.18 3.84 4.64
Accounts Payable Turnover
0.18 0.14 0.20 0.20
Inventory Turnover
1.28 0.91 1.28 1.13
Average Days of Payables
1,963.70 2,960.12 1,837.65 1,973.96
Days of Inventory on Hand
341.30 618.36 443.59 471.76
Tax Rate
0.01 (0.02) (0.21) (0.43)
Research and Development Expense of Revenue
25.12% 26.31% 54.06% 42.95%
Selling, General and Administrative Expense of Revenue
18.83% 20.06% 42.60% 34.47%
Share Based Compensation of Revenue
4.12% 4.31% 9.66% 8.39%
Interest Coverage
5.62 5.69 (0.35) 0.68
Operating CF/Net income
0.95 1.04 1.17 0.79
Depreciation/Fixed assets
3.12 0.40 0.55 0.72
Capex/Depreciation
(1.51) (0.40) (9.05) (7.25)
Revenue per Share
22.67 21.76 10.02 12.15
Operating CF per Share
9.12 8.94 (2.64) (0.37)
Capex per Share
(3.43) (0.11) (3.21) (3.25)
Capex to Sales
0.15 0.01 0.32 0.27

Fold the line items

Columns are period end dates